Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 113, Issue 3, Pages 725-734Publisher
WILEY
DOI: 10.1002/jcb.23402
Keywords
MELANOMA; IMMUNOTHERAPY; CANCER; ANTIBODIES; DENDRITIC CELLS; CTLA-4; T CELLS
Categories
Funding
- U.S. Department of Agriculture [58-1950-7-707]
- National Institute of Food and Agriculture (NIFA/USDA) [2010-65200-20395]
- NIFA [2010-65200-20395, 581257] Funding Source: Federal RePORTER
Ask authors/readers for more resources
Melanoma has traditionally been considered an immunogenic tumor. A number of approaches have been studied for enhancement of antitumor immunity. The first cytokine approved for the treatment of metastatic melanoma, interleukin-2, has resulted in prolonged responses in a small subset of patients, providing hope that immunotherapy might be useful for this disease. Ipilimumab, a monoclonal antibody to CTLA-4, was recently approved and a number of other promising investigational approaches are currently being pursued. This manuscript discusses more recent advances in the treatment of melanoma employing a variety of immune-enhancing approaches. J. Cell. Biochem. 113: 725734, 2012. (C) 2011 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available